A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy

Japanese Journal of Clinical Oncology

Volumn 39, Issue 6, 2009, Pages 367-375

  Inoue, Yasuhiro ^a   Toiyama, Yuji ^a   Tanaka, Koji ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; Oncologist related factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; UFT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; EUROPEAN UNION; HEALTH CARE POLICY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; SURVIVAL TIME; TREND STUDY; UNITED STATES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPEAN UNION; FEMALE; HUMANS; JAPAN; MALE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 66549090397     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp031     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-424.
3. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-7.
6. Köhne C-H, Van Cutsem E, Wils JA, Bokemeyer C, El-Serafi M, Lutz M, et al. Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986. Proc Am Soc Clin Oncol 2003;22:1018.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18: 2938-47.
8. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
9. Wagner JS, Adson MA, Van Heerden JA. The natural history of hepatic metastases from colorectal cancer: A comparison with resective treatment. Ann Surg 1984;199:502-8.
10. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10:40-8.
11. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
12. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
13. Grothey A, Deschler B, Kroening H, Ridwelski K, Peter Reichardt P, Kretzschmar A, et al. Phase III study of bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:512.
14. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
15. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 2007;370:143-52.
16. NCCN Clinical Practice Guidelines in Oncology, NCCN,V.1.2008. http://www.nccn.org/ (accessed 31 May 2008).
17. National Institute for Health and Clinical Excellence (NICE). http://www.nice.org.uk/ (accessed 31 May 2008).
18. Van Cutsem EJ, Kataja VV. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 2005;16(Suppl 1):i16-7.
19. Tveit KM, Kataja VV. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of rectal cancer. Ann Oncol 2005;16(Suppl 1):i20-1.
20. Van Cutsem EJ, Oliveira J, Kataja VV. ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of advanced colorectal cancer. Ann Oncol 2005;16(Suppl 1):i18-9.
21. Japanese Society for Cancer of the Colon and Rectum. JSCCR Guidelines 2005 for the Treatment of Colorectal Cancer. Tokyo: Kanehara Co. 2005.
22. Berrino F. The EUROCARE Study: Strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol 2003;14:9-13.
23. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al., EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: Results of the EUROCARE-4 study. Lancet Oncol 2007;8:773-83.
24. The Editorial Board of the Cancer Statistics in Japan. In: Kato H, Sobue T, Katano K, Saito Y, Tsukuma H, Saruki N, et al., editors. Cancer Statistics in Japan 2007. Tokyo: Foundation for Promotion Cancer Research (FPCR) 2007,46.